Precigen Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Precigen Inc 's ROA in the first quarter of 2026?
Precigen Inc recorded a cumulative net loss of $-204 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -144.39%.

However, within the Healthcare sector 807 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4394, from total ROA ranking in the fourth quarter of 2025 at 5155.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	11.03 %	11.41 %	110.11 %	41.79 %	-3.94 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-204	-251	-247	-125	-157
Return On Assets (TTM)	-144.39 %	-181.47 %	-184.13 %	-111.32 %	-149.89 %
PGEN's Total Ranking	# 4394	# 5155	# 4580	# 4487	# 4666
Total Assets (TTM) in million	139	158	170	99	125
Seq. Total Assets Change	-11.96 %	-6.86 %	70.5 %	-20.59 %	-11.66 %
Seq. Net Income Change	-	-	-	-	-

PGEN's 5 Years Annual ROA >> Back to PGEN Management Effectiveness >> Compare PGEN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 381
Sector	# 808
Overall	# 4351

Return On Assets Statistics
High	Average	Low
10.01 %	-65.5 %	-180.45 %
(Dec 31 2022)		(Sep 30 2025)

Financial Statements
Precigen Inc 's Assets	$ 139 million	PGEN's Balance sheet
Precigen Inc 's Income	$ -8 million	Quarterly PGEN's Income Statement
PGEN's Income by Division		See PGEN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	11.41 %	-2.97 %	-30.01 %	-40.45 %	-23.04 %
Total Assets in million	158	142	146	209	351
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-251	-126	-96	28	-92
Annual Return On Assets	-158.62 %	-89 %	-65.61 %	13.56 %	-26.28 %

PGEN's 5 Years Annual ROA >> Back to PGEN Management Effectiveness >> Compare PGEN ROA to its Competitors

More Return On Assets Ratios
PGEN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PGEN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PGEN's Competitors
Subscribers only: Roa for Precigen Inc 's Suppliers
Subscribers only: Return On Assets for PGEN's Customers

You may also want to know
PGEN's Roi	PGEN's Inventory Turnover Ratio	PGEN's Growth Rates	PGEN's Dividend Comparisons
	PGEN's Profitability Ratios	PGEN's Asset Turnover Ratio	PGEN's Dividend Growth
PGEN's Roe	PGEN's Valuation Ratios	PGEN's Financial Strength Ratios	PGEN's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:06:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.